[Disclosure] Celltrion (068270) Obtains South Korean Phase 3 Clinical Trial Approval for ‘CT-P13 SC’ (Remsima SC) in Pediatric Ulcerative Colitis

Source: Financial Supervisory Service Dart System / 2025-02-24

Disclosure Type: Key Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has obtained approval for its Phase 3 clinical trial application (IND) from the Ministry of Food and Drug Safety (MFDS) of South Korea for ‘CT-P13 SC’, a subcutaneous formulation of infliximab, in pediatric patients with active ulcerative colitis.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Trial Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis
• Clinical Phase & Agency: Phase 3 Clinical Trial / Ministry of Food and Drug Safety (MFDS) of South Korea
• Target Indication: Pediatric Patients (aged 6-17) with Moderately to Severely Active Ulcerative Colitis
• Timeline:
  • Application Date: September 30, 2024
  • Approval Date: February 21, 2025 (Official document confirmed date)
• Trial Design & Scale:
  • Number of Subjects: 243 patients
  • Trial Duration: Treatment period of 106 weeks
  • Study Design: Randomized, double-blind, Phase 3 clinical trial
• Trial Objective & Background:
  • Objective: To compare and evaluate the efficacy of low-dose and high-dose maintenance therapy of CT-P13 SC administered every two weeks to achieve clinical remission at Week 54.
  • Background: While CT-P13 SC has completed Phase 3 trials for adult patients (ulcerative colitis and Crohn’s disease) and secured marketing authorization in multiple markets including the US and Europe, this study aims to expand therapeutic options to the pediatric population.

📈 2. [Expert Perspective: What This Means for Investors]

• Initiation of Clinical Evaluation for Pediatric Indication: This disclosure confirms that CT-P13 SC, which is already authorized for adult indications in major markets, has cleared the regulatory hurdle for its pediatric ulcerative colitis Phase 3 trial in South Korea. This permits the company to formally generate local clinical safety and efficacy data for this younger patient population.
• Long-Term Study and Observation Window: The approved study protocol involves a 106-week treatment duration tracking 243 pediatric subjects to compare low-dose and high-dose administration regimens. Consequently, clinical milestones related to this study will unfold over a prolonged timeline, with a key interim endpoint scheduled at Week 54.
• Inherent Clinical R&D Risks: As noted in the disclosure’s caution notes, the historical probability of a clinical candidate successfully securing final regulatory approval is approximately 10%. Investors should recognize that unexpected clinical results could lead to a redirection or termination of commercialization plans, keeping clinical development risks in perspective.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has secured regulatory approval from the South Korean MFDS for its Phase 3 clinical trial evaluating its subcutaneous infliximab formulation, ‘CT-P13 SC’, in pediatric ulcerative colitis. This authorization, received approximately five months after filing the application in September 2024, establishes the official framework to expand the therapeutic scope of this biologic candidate from adult cohorts to pediatric patients.

The primary check point for investors moving forward is the actual initiation of the Phase 3 trial, such as the enrollment and dosing of the first patient under the approved protocol. Since the study involves a long-term tracking structure with a 106-week treatment duration, closely monitoring whether clinical progression meets the regulatory schedule will be essential.

Additionally, because the general statistical success rate for a candidate to successfully secure final marketing approval stands at approximately 10%, investors should avoid interpreting this clinical plan approval as an immediate indicator of commercial success. Following the objective clinical metrics and updates published in upcoming periodic corporate reports remains the recommended approach.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.